Onset of action of the beta 3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder

Christopher R. Chapple, Victor W. Nitti, Vik Khullar, Jean Jacques Wyndaele, Sender Herschorn, Philip van Kerrebroeck, Mary Beth Blauwet, Emad Siddiqui

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1565-1572
JournalWorld Journal of Urology
Volume32
Issue number6
DOIs
Publication statusPublished - Dec 2014

Keywords

  • Mirabegron
  • Overactive bladder
  • beta(3)-Adrenoceptor agonist
  • Onset of action

Cite this

Chapple, C. R., Nitti, V. W., Khullar, V., Wyndaele, J. J., Herschorn, S., van Kerrebroeck, P., Blauwet, M. B., & Siddiqui, E. (2014). Onset of action of the beta 3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder. World Journal of Urology, 32(6), 1565-1572. https://doi.org/10.1007/s00345-014-1244-2